BMRA BIOMERICA INC
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 73290 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-11.2%
TTM net income YoY-37.0%
TTM EPS YoY-9.2%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—
Margins
Gross margin0.9%
Operating margin-125.2%
Net margin-115.5%
FCF margin—
EBITDA margin-123.6%
Returns
ROE-113.8%
ROA-67.1%
ROIC (approx.)-284.4%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets54.8%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-08-31 | 2026Q4*2026-05-31 | 2026Q32026-02-28 | 2026Q22025-11-30 | 2026Q12025-08-31 | 2025Q4*2025-05-31 | 2025Q32025-02-28 | 2025Q22024-11-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.26M | $875,000 | $987,000 | $1.21M | $1.38M | $749,000 | $1.12M | $1.64M |
| Cost of revenue | $1.16M | $946,000 | $1.03M | $1.16M | $956,000 | $993,000 | $1.10M | $1.20M |
| Gross profit | $103,000 | -$71,000 | -$44,000 | $51,000 | $424,000 | -$244,000 | $19,000 | $437,000 |
| R&D expense | $206,000 | $205,000 | $178,000 | $193,000 | $212,000 | $252,000 | $217,000 | $257,000 |
| SG&A expense | $1.12M | $1.26M | $1.08M | $1.23M | $1.33M | $1.07M | $1.01M | $1.17M |
| Operating income | -$1.23M | -$1.53M | -$1.30M | -$1.37M | -$1.12M | -$1.56M | -$1.21M | -$993,000 |
| Pretax income | -$1.23M | -$1.14M | -$1.30M | -$1.31M | $5,000 | -$1.54M | -$1.17M | -$953,000 |
| Income tax | $6,000 | $6,000 | $8,000 | $5,000 | $3,000 | $5,000 | -$4,000 | -$3,000 |
| Net income | -$1.23M | -$1.15M | -$1.31M | -$1.32M | $2,000 | -$1.54M | -$1.16M | -$950,000 |
| EBITDA | -$1.21M | -$1.52M | -$1.28M | -$1.35M | -$1.10M | -$1.54M | -$1.19M | -$971,000 |
| EPS (basic) | -0.37 | — | -0.44 | -0.45 | 0.00 | — | -0.48 | -0.06 |
| EPS (diluted) | -0.37 | — | -0.44 | -0.45 | 0.00 | — | -0.48 | -0.06 |
| Weighted avg. shares (diluted) | 3.30M | — | 3.01M | 2.91M | 2.64M | — | 2.40M | 2.14M |
| Balance sheet | ||||||||
| Cash & equivalents | $2.73M | $1.31M | $1.34M | $2.54M | $3.05M | $2.40M | $3.06M | $2.37M |
| Receivables | $897,000 | $785,000 | $941,000 | $947,000 | $1.21M | $731,000 | $1.27M | $1.33M |
| Inventory | $1.63M | $1.71M | $1.65M | $1.52M | $1.47M | $1.49M | $1.66M | $1.79M |
| Current assets | $5.41M | $4.02M | $4.12M | $5.19M | $5.90M | $4.88M | $6.20M | $5.95M |
| PP&E, net | $68,000 | $78,000 | $91,000 | $105,000 | $120,000 | $135,000 | $151,000 | $167,000 |
| Intangibles | $204,000 | $209,000 | $231,000 | $219,000 | $223,000 | $228,000 | $234,000 | $236,000 |
| Total assets | $8.07M | $6.76M | $4.88M | $6.03M | $6.85M | $5.95M | $7.38M | $7.27M |
| Current liabilities | $2.84M | $2.48M | $1.56M | $1.60M | $1.69M | $1.74M | $1.65M | $1.88M |
| Total liabilities | $4.42M | $4.13M | $1.56M | $1.60M | $1.70M | $1.84M | $1.84M | $2.16M |
| Shareholders' equity | $3.65M | $2.63M | $3.32M | $4.43M | $5.16M | $4.11M | $5.53M | $5.11M |
| Shares outstanding | 4.60M | 3.20M | 3.03M | 2.95M | 2.82M | 2.55M | 20.37M | 18.34M |
| Cash flow statement | ||||||||
| Operating cash flow | -$802,000 | -$912,000 | -$1.25M | -$991,000 | -$268,000 | -$661,000 | -$1.04M | -$791,000 |
| Investing cash flow | — | $18,000 | — | — | — | $0 | -$4,000 | — |
| Financing cash flow | $2.23M | $871,000 | $61,000 | $482,000 | $920,000 | -$5,000 | $1.74M | — |
| Depreciation & amortization | $15,000 | $17,000 | $20,000 | $20,000 | $20,000 | $23,000 | $21,000 | $22,000 |
| Stock-based compensation | $134,000 | $91,000 | $58,000 | $72,000 | $133,000 | $108,000 | $91,000 | $155,000 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.